referring to reuters
Lilly cancer drug hits hurdle, panel recommends study continue
Lilly cancer drug hits hurdle, panel recommends study continue
An independent panel's interim analysis of Eli Lilly and Co's breast cancer drug abemaciclib showed the treatment did not meet the effectiveness criteria in a late-stage trial.The panel recommended the trial continue through the first half of 2017, the company said on Wednesday.If approved, abemaciclib is expected to compete with Pfizer Inc's breast cancer drug, Ibrance, which brought in over half a billion dollars in second-quarter sales.The trial is designed to evaluate the safety and efficacy of abemaciclib, in combination with anti-estrogen drug fulvestrant, in patients with a form of advanced breast cancer.
moreover from bostonglobe
AstraZeneca cancer drug selumetinib fails in lung trial
AstraZeneca cancer drug selumetinib fails in lung trial
The selumetinib study results are disappointing but the financial impact will be negligible, according to an AstraZeneca spokeswoman.AstraZeneca's experimental medicine selumetinib failed to keep a common form of lung cancer at bay in an advanced clinical test, making it the second drug maker to report a setback in battling tumors of the lung this month.The drug, combined with chemotherapy, didn't help patients live longer or prevent the disease from worsening, the two goals being sought by researchers in the trial, the London-based drug maker said in a statement on Tuesday.AdvertisementBristol-Myers Squibb Co. said Friday its cancer medicine Opdivo failed in a study that would have been the basis for widely expanding its use, sending the stock of the US drug maker plummeting.
as well cancerresearchuk
Dundee research explains drug resistance in ovarian cancer
Dundee research explains drug resistance in ovarian cancer
Scientists in Dundee have uncovered important information about how ovarian cancer becomes resistant to certain treatments, according to research published in the British Journal of Cancer*."Our study shows an important resistance mechanism which is common to drugs used routinely in the clinic and to new drugs which are being tested in clinical trials."- Dr Gillian SmithThe researchers discovered that a gene called ABCB1, which is known to play a role in resistance to the chemotherapy drug paclitaxel in ovarian cancers, also causes resistance to other ovarian cancer treatments.Women with ovarian cancer are commonly treated with a combination of carboplatin and paclitaxel, but if their cancer stops responding, doctors need other options.
No comments:
Post a Comment